Suppliers and packagers for generic pharmaceutical drug: DAROLUTAMIDE

DAROLUTAMIDE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Bayer Healthcare	NUBEQA	darolutamide	TABLET;ORAL	212099	NDA	Bayer HealthCare Pharmaceuticals Inc.	50419-395-01	1 BOTTLE in 1 CARTON (50419-395-01) / 120 TABLET, FILM COATED in 1 BOTTLE	2019-07-31
Bayer Healthcare	NUBEQA	darolutamide	TABLET;ORAL	212099	NDA	Bayer HealthCare Pharmaceuticals Inc.	50419-395-72	1 BOTTLE in 1 CARTON (50419-395-72) / 120 TABLET, FILM COATED in 1 BOTTLE	2019-07-31

Darolutamide Suppliers: Manufacturing Landscape and Key Players

Last updated: February 19, 2026

This report identifies the primary suppliers involved in the manufacturing of darolutamide, a non-steroidal androgen receptor inhibitor used in the treatment of prostate cancer. The analysis details API manufacturers, key intermediates, and the supply chain structure, highlighting potential risks and strategic considerations for pharmaceutical companies.

Who Manufactures Darolutamide Active Pharmaceutical Ingredient (API)?

The manufacturing of darolutamide API is concentrated among a select group of specialized chemical manufacturers. These companies possess the technical expertise and regulatory compliance necessary for complex organic synthesis and Good Manufacturing Practices (GMP) production.

• Bayer AG: As the originator and primary marketer of darolutamide (Nubeqa®), Bayer AG maintains significant internal manufacturing capabilities for the API. This vertical integration provides a high degree of control over quality, supply, and intellectual property.
• Contract Manufacturing Organizations (CMOs): Several CMOs operate as authorized suppliers for Bayer, producing darolutamide API under stringent quality agreements. Identification of these specific CMOs is often proprietary, but they are typically located in regions with established pharmaceutical chemical manufacturing infrastructure, such as Europe and Asia. These CMOs are subject to rigorous auditing and qualification by Bayer.
• Key Geographic Hubs: API manufacturing for darolutamide is likely concentrated in regions with a strong pharmaceutical chemical industry, including:
  • Germany: Leveraging Bayer’s established presence and expertise.
  • India: A global hub for API production, known for cost-effectiveness and scalability.
  • China: Another significant player in global API manufacturing, offering extensive production capacity.

What Are the Critical Intermediates in Darolutamide Synthesis?

The synthesis of darolutamide involves a multi-step process requiring the production of several key chemical intermediates. Disruptions in the supply of these intermediates can significantly impact the overall darolutamide supply chain.

• Core Structural Components: The molecule's core structure is built from specific chiral and aromatic building blocks. Procurement of these starting materials is a critical upstream consideration.
• Registered Intermediates: Specific intermediates are designated as "registered intermediates" by regulatory authorities. Their manufacturing sites and quality control are closely monitored as part of the drug master file (DMF) or equivalent submissions. Any change in the supplier or manufacturing process of a registered intermediate requires regulatory notification and approval.
• Supplier Diversity: While some intermediates may be sourced from a single supplier due to proprietary synthesis routes or specialized manufacturing requirements, efforts are typically made to establish secondary suppliers for critical intermediates to mitigate supply chain risk.
• Examples of Intermediate Classes (General, Specific proprietary intermediates are not publicly disclosed):
  • Substituted Pyrazoles: Formation of the pyrazole ring system is a foundational step.
  • Chiral Amines: Introduction of stereochemistry often requires specialized chiral amine precursors.
  • Aryl Halides/Boronic Acids: Coupling reactions utilizing these reagents are common in modern pharmaceutical synthesis.

How is the Darolutamide Supply Chain Structured?

The darolutamide supply chain is a complex network involving raw material sourcing, intermediate synthesis, API manufacturing, formulation, and final drug product packaging.

• Upstream: This segment includes the sourcing of basic chemicals and solvents from global chemical suppliers. The quality and consistency of these raw materials are paramount.
• Midstream: This is where the complex organic synthesis of intermediates and the final API occurs. This stage is heavily regulated and requires specialized chemical manufacturing facilities and expertise. Bayer likely oversees its own internal API production and manages a network of qualified CMOs for intermediate and API synthesis.
• Downstream: This involves the formulation of the API into the final dosage form (tablets) and packaging. This is typically conducted at dedicated pharmaceutical manufacturing sites, either owned by Bayer or by specialized contract drug product manufacturers.
• Logistics and Distribution: A global logistics network ensures the timely and secure transportation of materials and finished products across international borders, adhering to temperature and handling requirements.

Table 1: Darolutamide Supply Chain Stages and Considerations

Stage	Activities	Key Considerations	Potential Risks
Raw Materials	Sourcing of basic chemicals, solvents, reagents.	Purity, supplier qualification, geopolitical stability, cost.	Quality variability, single-source dependency, trade restrictions.
Intermediates	Multi-step synthesis of complex chemical building blocks.	Process validation, IP protection, regulatory compliance (registered intermediates).	Synthesis route challenges, scalability issues, regulatory scrutiny on specific sites.
API Mfg.	Final synthesis and purification of darolutamide API.	GMP compliance, stringent quality control, capacity, DMF filing.	Capacity constraints, GMP deviations, supply disruptions from key manufacturers.
Formulation	Blending API with excipients, granulation, tablet compression.	Excipient compatibility, process robustness, stability testing, site validation.	Excipient shortages, cross-contamination, equipment failure, batch failures.
Packaging	Blistering, bottling, labeling, secondary packaging.	Packaging material sourcing, serialization, tamper-evident features, regulatory compliance.	Packaging material defects, counterfeit risks, labeling errors.
Distribution	Warehousing, transportation to wholesalers and pharmacies.	Cold chain management (if applicable), customs clearance, security, route optimization.	Transit delays, temperature excursions, theft, geopolitical disruptions.

What Are the Regulatory and Quality Control Aspects?

The manufacturing of darolutamide and its intermediates is subject to rigorous global regulatory oversight to ensure patient safety and product efficacy.

• Good Manufacturing Practices (GMP): All manufacturing of API and finished drug products must comply with GMP guidelines established by regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and others. This includes strict controls over facilities, equipment, personnel, documentation, and quality assurance.
• Drug Master Files (DMFs): Suppliers of API and key intermediates typically maintain DMFs with regulatory authorities. These confidential documents detail the manufacturing process, facilities, quality controls, and stability data. Pharmaceutical companies reference these DMFs in their own marketing authorization applications.
• Auditing and Qualification: Pharmaceutical companies, including Bayer, conduct extensive audits of their suppliers to ensure compliance with quality standards and regulatory requirements. This qualification process is ongoing and critical for supply chain integrity.
• Impurity Profiling: Manufacturers must identify, quantify, and control impurities within strict limits defined by regulatory guidelines. This requires sophisticated analytical techniques.
• Change Control: Any significant change in the manufacturing process, raw materials, or facilities for API or registered intermediates must be managed through a formal change control system and may require regulatory notification or approval.

Who Are the Key Players and Potential Sourcing Strategies?

The supply of darolutamide involves originator control, established CMOs, and potentially secondary suppliers for certain raw materials and intermediates.

• Bayer AG: Holds the primary manufacturing and distribution rights. Internal manufacturing and a closely managed network of CMOs are central to their strategy.
• Specialized API Manufacturers: Large CMOs with strong capabilities in complex organic synthesis and GMP production are the likely partners for API and registered intermediate manufacturing. These may include companies with expertise in heterocyclic chemistry and chiral synthesis.
• Intermediate Suppliers: A wider range of chemical suppliers may provide earlier-stage raw materials and non-registered intermediates. Diversification here can reduce risk.
• Geographic Diversification: Sourcing from multiple geographic regions can mitigate risks related to geopolitical instability, natural disasters, or localized regulatory changes. However, this also increases supply chain complexity and requires robust oversight.
• Dual Sourcing: For critical intermediates, establishing relationships with two or more qualified suppliers is a common risk mitigation strategy, although challenging for highly specialized or patented synthesis steps.

What Are the Risks and Mitigation Strategies?

The darolutamide supply chain faces several inherent risks that require proactive management.

• Supply Chain Disruptions: Events such as natural disasters, geopolitical conflicts, pandemics, or regulatory crackdowns on manufacturing sites can interrupt supply.
  • Mitigation: Geographic diversification of suppliers, maintaining safety stock of critical materials and API, and developing robust business continuity plans.
• Quality Failures: Deviations from GMP or inconsistent quality of raw materials or intermediates can lead to batch rejections, recalls, and regulatory action.
  • Mitigation: Rigorous supplier qualification and auditing programs, stringent in-process and final product testing, and a strong quality culture within manufacturing sites.
• Intellectual Property (IP) Infringement: Unauthorized manufacturing or sale of darolutamide or its intermediates poses a significant IP risk.
  • Mitigation: Strict contractual agreements with suppliers, active monitoring of the market for infringing products, and legal enforcement.
• Capacity Constraints: Rapid increases in demand for darolutamide could outstrip existing manufacturing capacity.
  • Mitigation: Long-term capacity planning with key manufacturing partners, exploring opportunities for process optimization to increase throughput, and pre-qualification of secondary manufacturing sites.
• Regulatory Changes: Evolving regulatory requirements in different jurisdictions can impact manufacturing processes and compliance.
  • Mitigation: Staying abreast of global regulatory trends, maintaining open communication with regulatory agencies, and ensuring flexible manufacturing processes that can adapt to changes.
• Cost Volatility: Fluctuations in the cost of raw materials, energy, and labor can impact the overall cost of goods.
  • Mitigation: Negotiating long-term supply agreements, exploring alternative sourcing for key raw materials, and optimizing manufacturing processes for efficiency.

Key Takeaways

• Bayer AG is the primary manufacturer and licensor of darolutamide, maintaining significant internal control over API production.
• The synthesis of darolutamide relies on specialized chemical intermediates, with registered intermediates requiring stringent regulatory oversight.
• A robust supply chain structure is essential, involving upstream chemical suppliers, midstream API/intermediate manufacturers (including CMOs), and downstream formulation/packaging sites.
• Compliance with GMP and detailed regulatory filings (e.g., DMFs) are critical throughout the manufacturing process.
• Key risks include supply chain disruptions, quality failures, IP infringement, and capacity constraints, all of which necessitate proactive mitigation strategies.

Frequently Asked Questions

1. Can generic manufacturers produce darolutamide before patent expiry?

Generic manufacturers can only produce darolutamide after the relevant patents covering the compound, its use, and potentially its manufacturing processes have expired or are successfully challenged. The patent landscape for darolutamide is complex and includes composition of matter, formulation, and method of use patents.

2. How does Bayer ensure the quality of API sourced from CMOs?

Bayer implements a comprehensive supplier qualification and ongoing monitoring program. This includes rigorous audits of CMO facilities for GMP compliance, detailed review of quality control data, validation of manufacturing processes, and establishment of stringent quality agreements.

3. What are the typical lead times for sourcing critical intermediates for darolutamide?

Lead times can vary significantly based on the complexity of the intermediate, the supplier's existing capacity, and raw material availability. For highly specialized or custom-synthesized intermediates, lead times can range from several months to over a year.

4. Are there publicly listed CMOs that manufacture darolutamide API?

Specific CMOs manufacturing darolutamide API under contract for Bayer are generally not publicly disclosed due to confidentiality agreements and competitive sensitivity. Information on approved API manufacturers is typically found in regulatory filings, but specific product-to-manufacturer links are often proprietary.

5. What is the impact of geopolitical instability on the darolutamide supply chain?

Geopolitical instability can lead to trade disruptions, export/import restrictions, increased shipping costs, and potential delays in raw material or finished product movement. Manufacturers mitigate this by diversifying their supplier base geographically and maintaining strategic inventory levels.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Good Manufacturing Practice (GMP). Retrieved from [FDA Website - General GMP Information] (Note: Specific URL would vary, general reference to FDA GMP guidance). [2] European Medicines Agency. (n.d.). Good manufacturing practice. Retrieved from [EMA Website - GMP Information] (Note: Specific URL would vary, general reference to EMA GMP guidance). [3] U.S. Food and Drug Administration. (n.d.). Drug Master Files (DMFs). Retrieved from [FDA Website - DMF Information] (Note: Specific URL would vary, general reference to FDA DMF guidance).